PatientsVille.com Logo

HYPERHIDROSIS and OMEPRAZOLE

PatientsVille

HYPERHIDROSIS Symptoms and Causes

Sweat is a clear, salty liquid produced by glands in your skin. Sweating is how your body cools itself. You sweat mainly under your arms and on your feet and palms. When sweat mixes with bacteria on your skin, it can cause a smell. Bathing regularly and using antiperspirants or deodorants can help control the odor.

Sweating a lot is normal when it is hot or when you exercise, are anxious, or have a fever. It also happens during menopause. If you often sweat too much, it's called Hyperhidrosis. Causes include thyroid or nervous system disorders, low blood sugar, or another health problem.

Sweating too little, anhidrosis, can be life-threatening because your body can overheat. Causes of anhidrosis include dehydration, burns, and some skin and nerve disorders.

Check out the latest treatments for HYPERHIDROSIS

HYPERHIDROSIS treatment research studies

OMEPRAZOLE clinical trials, surveys and public health registries


Find Drug Side Effect reports



OMEPRAZOLE Side Effects

Hypomagnesaemia (418)
Diarrhoea (311)
Hypocalcaemia (288)
Nausea (285)
Renal Failure Acute (241)
Vomiting (240)
Dyspnoea (225)
Dizziness (205)
Gastrooesophageal Reflux Disease (191)
Fatigue (168)
Pain (164)
Abdominal Pain (163)
Headache (157)
Malaise (155)
Dyspepsia (152)
Rash (148)
Asthenia (146)
Fall (137)
Abdominal Pain Upper (133)
Confusional State (130)
Hypokalaemia (126)
Condition Aggravated (125)
Pruritus (120)
Arthralgia (118)
Anxiety (117)
Tubulointerstitial Nephritis (116)
Pyrexia (116)
Hyponatraemia (115)
Product Substitution Issue (113)
Paraesthesia (112)
Weight Decreased (111)
Muscle Spasms (109)
Anaemia (106)
Decreased Appetite (104)
Chest Pain (100)
Dysphagia (93)
Convulsion (88)
Dehydration (86)
Depression (84)
Cough (84)
Lethargy (79)
Urticaria (78)
Constipation (78)
Muscular Weakness (78)
Pain In Extremity (76)
Myalgia (76)
Tetany (73)
Tremor (73)
Oedema Peripheral (73)
Pneumonia (72)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

I started taken omeprazole. I ran out of my Nexum well I started itching really bad as it I had bug bites believe me I will never uses this again. I've never had reaction to a med before

I stopped taking Omeprazole 20mg after 4 days because of a side effect, strong palpitations most of the time; I stopped taking them a week ago and still have the palpitations. It's very scary........

I am experiencing itching on my arms, rashes on arms and shoulders, hoarseness, slight dizziness, trouble sleeping and mild headaches. I was prescribed this medication for treatment of bloating caused by my hiatal hernia but can

After 2 weeks skin burning on chest and back nevrous sytoms O:-) :'(

After the 1st week I suffered from severe dizzyness, nausea and headaches. Vomited everything I ate. Yet around 5pm I would always feel relatively human again.

An update, It has only been 3 days & my arm pain has gone!!, for anybody suffering similar symptoms to mine this is what i done...1.STOP taking omeprazole. 2. buy plenty bottled water & drink upto 6 bottles per day. 3 eat healthy (det

Been taking omeprazole for 6 years. during that time diagnosed with osteoporsis. after reading about this seems any proton pump inhibitor can cause. so angry with doctor. looking now for new drug, severe gerd and hiatal hernia.

Both arms , upper arm muscle weakness and pain, , dosage 40mg twice a day

By day 4 severe leg pain, joing pain and cramping and prior never had this pain. All my muscles appear to be tighting up and going to discontinue this ASAP. I guess I am having a very rare reation to Prilosec.

Could the omeprazole be causing sking irritation and the spots that have appeared in my scalp, i was much better when i was taking lanzoperazole

I have experienced a mild form of hyperhidrosis since I was in middle school. Through highschool, I would tape paper towels under my arms, wear tanktops, put on an insane amount of deodorant and put baby powder on three times a day.&nbs

HYPERHIDROSIS Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Not yet recruiting Botulinum Toxin Treatment in Craniofacial, Inguinal, Palmar, Plantar and Truncal Hyperhidrosis
Condition: Hyperhidrosis
Interventions: Drug: Botox (onabotulinumtoxinA);   Drug: NeuroBloc/Myobloc (rimabotulinumtoxinB);   Drug: NaCl (placebo)
Outcome Measures: DLQI (Dermatology Life Quality Index);   AE (Adverse Events);   Gravimetry;   HDSS (Hyperhidrosis Disease Severity Scale);   Health outcome (EQ-5D);   LSAS-SR (Liebowitz Social Anxiety Scale-Self Report);   MADRS-S (Montgomery-Asberg Depression Rating Scale-Self report);   Global Assessment of Therapy
2 Not yet recruiting Evaluate the Efficacy of Oxybutynin Chloride in Patients With Primary Hyperhidrosis
Condition: Primary Hyperidrosis
Interventions: Drug: Oxybutynin;   Drug: Placebo
Outcome Measures: Oxybutynin Chloride efficacy;   Perception of improvement;   Evaluate therapeutic safety;   Quality of life;   Time of subject response;   Duration of response;   Evaluation between quality of life and groups
3 Recruiting Histological Analysis Following Ulthera System Treatment for Hyperhidrosis
Condition: Hyperhidrosis
Intervention: Device: Ulthera System Treatment
Outcome Measures: Reduction in the number of sweat glands from baseline to 90-days post-treatment.;   Reduction in spontaneous axillary sweat production assessed by gravimetric method at 90-days post treatment;   HDSS score reduction;   Starch iodine test
4 Recruiting Tx Axillary Hyperhidrosis 1210nm Diode Laser
Condition: Axillary Hyperhidrosis
Intervention: Device: 1210nm Diode Laser treatments
Outcome Measures: subjective global assessment questionnaire;   gravimetric analysis;   modified starch-iodine test
5 Recruiting Comparator Study of the Effect of DRM04B and DRM 04 in Subjects With Axillary Hyperhidrosis
Condition: Hyperhidrosis
Interventions: Drug: Dose 1 of DRM04B;   Drug: Dose 2 of DRM04B;   Drug: Dose 1 of DRM04;   Drug: Dose 2 of DRM04;   Other: Vehicle
Outcome Measures: Proportion of subjects who have a minimum 1-grade improvement in HDSS from Baseline at Week 4;   Proportion of subjects who have a minimum 2-grade improvement in HDSS from Baseline at Week 4;   Absolute change in the gravimetrically measured sweat production from Baseline to Week 4;   Absolute change in the gravimetrically measured sweat production from Baseline to Week 6;   Proportion of subjects who have a minimum 1-grade improvement in HDSS from Baseline at Week 6
6 Recruiting A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
Condition: Hyperhidrosis
Intervention: Drug: BBI-4000
Outcome Measures: Percent change in the gravimetrically measured sweat production from baseline;   Absolute change in the gravimetrically measured sweat production from baseline;   Proportion of subjects who have a minimum of 2-grade improvement in HDSS from baseline.;   Proportion of subjects who have a minimum of 1-grade improvement in HDSS from baseline
7 Recruiting Characterization of Exposure From Topical Administration of [14C] Umeclidinium to Axilla or Palm of Healthy Male Subjects
Condition: Hyperhidrosis
Intervention: Drug: [14C]Umeclidinium 18.5 mg
Outcome Measures: PK Assessment (Cmax) for [14C] umeclidinium and total radioactivity;   PK Assessment (tmax) for [14C] umeclidinium and total radioactivity;   PK Assessment (AUC) for [14C] umeclidinium and total radioactivity;   PK Assessment (t1/2) for [14C] umeclidinium and total radioactivity;   Compartmental modeling of absorption rate for [14C] umeclidinium;   Compartmental modeling of elimination rate for [14C] umeclidinium;   Determine the amount of Umeclidinium absorbed in the skin;   Safety Assessment for AEs;   Safety Assessment for ECGs, and telemetry;   Safety Assessment for hematology laboratory parameters;   Safety Assessment for measurement of blood pressure;   Number of subjects with application site skin irritation;   Safety Assessment for clinical chemistry laboratory parameters;   Safety Assessment for measurement of pulse rate
8 Recruiting Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Glycopyrrolate (AIDES-G)
Conditions: Hyperhydrosis;   Depression
Intervention: Drug: Glycopyrrolate
Outcome Measures: Clinical Global Impression- Improvement scores;   change in mean of patient rated severity of sweating for each week, and change in mean skin conductance for each week
9 Recruiting Efficacy and Safety of Sage Tablets Compared to Placebo in Menopausal Patients With Hot Flushes and Sweating
Condition: Menopausal Hot Flushes
Intervention: Drug: Sage extract, 3400 mg , DER 1:17
Outcome Measures: Change from Baseline Hyperhidrosis Disease Severity Scale;   Change from Baseline Menopause Rating Scale / MRS;   Change from Baseline Modified Dem Tect
10 Recruiting Comparison of Methods of Lumbar Sympathetic Ganglion Block: Distance vs Angle
Condition: Lumbar Sympathetic Ganglion Block Indication: Neuropathic Pain, CRPS, Hyperhydrosis Etc.
Intervention: Procedure: lumbar sympathetic ganglion block
Outcome Measures: temperature change;   muscle or vessel shadow
11 Not yet recruiting ASIS for Enbrel in Plaque Psoriasis
Condition: Plaque Psoriasis.
Interventions: Drug: Gadolinium;   Drug: Efficacy of Enbrel subcutaneously at Week 12;   Drug: Efficacy of Enbrel subcutaneously at Week 24;   Drug: Efficacy of Enbrel subcutaneously at Week 36;   Drug: Efficacy of Enbrel subdermally at Week 12;   Drug: Efficacy of Enbrel subdermally at Week 24;   Drug: Efficacy of Enbrel subdermally at Week 36;   Drug: PASI 75 n(%) subcutaneously at Week 12;   Drug: PASI 75 n(%) subcutaneously at Week 24;   Drug: PASI 75 n(%) subcutaneously at Week 36;   Drug: PASI 75 n(%) subdermally at Week 12;   Drug: PASI 75 n(%) subdermally at Week 24;   Drug: PASI 75 n(%) subdermally at Week 36;   Drug: Adverse Reactions of Enbrel subcutaneously;   Drug: Adverse Reactions of Enbrel subdermally at Week 36
Outcome Measures: Relative Prolongation Ability Score for Gadolinium subdermally injected.;   Efficacy of Enbrel subcutaneously vs. subdermally in Plaque Psoriasis.
12 Unknown  Inherited Myokymia: A Clinical and Genetic Study of a Family
Condition: A Study of Clinical and Genetic Mutations in a Family of Neuromyotonia, so Called Isaac's Syndrome
Intervention:
Outcome Measure:
13 Not yet recruiting Single-port Thoracoscopic Sympathicotomy in Complex Regional Pain Syndrome Type I (CRPS)
Condition: Complex Regional Pain Syndrome Type I of the Upper Limb
Intervention: Procedure: unilateral single-port VATS sympathicotomy
Outcome Measures: Change in perceived pain measured in Visual Analogue Scale;   Change in function in extremity